Results 291 to 300 of about 14,444,288 (391)
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp+13 more
wiley +1 more source
Pericytes: The forgotten controllers of a functional blood-brain barrier. [PDF]
Roedel M, Brooks N, Lamb TJ.
europepmc +1 more source
Contrasting Functions of Notch Signaling In Normal and Pathogenic Adrenal Biology. [PDF]
Derek P. Simon
openalex
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald+18 more
wiley +1 more source
Editorial: Electric stimulation in the eye and brain: advancements and applications. [PDF]
Shu DY, Nakano Y, Cho KS, Lennikov A.
europepmc +1 more source
Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias+12 more
wiley +1 more source
Testing the feasibility and utility of an executive function battery for use with primary school-aged students in Malawi. [PDF]
Willoughby MT+4 more
europepmc +1 more source